Life Sciences Archive » March, 2013

Life Sciences - March, 2013

290 articles

• FDA Greenlights J&J's Controversial Diabetes Drug
• Alphatec Shakes Securities Suit Over French Firm Buy
• 6 Health Policies A Gridlocked Congress Can Get Behind
• Pfizer Can't Shake Securities Action Over Celebrex Risks
• Medtronic Asks High Court To Weigh IP Case Burden Of Proof
• Ropes & Gray Aids TPG In $173M Chinese Pharma Buyout
• US Wins $10M Judgment For Illegal Primrose Oil Imports
• DePuy Hip Implant Patient Tells Jury Of Pain After Surgeries
• Generic Darvocet Cos.' Mass Action Jurisdiction Claim Denied
• Allergan Drops Patent, Ad Claims Over Eyelash Drug Latisse
• Reading The Labels Of Par And Harkonen
• Product Makers Stand To Profit From Pa. Tort Law Change
• Texas Attorney Stole Pfizer Settlement, Ex-Clients Say
• Alexion Gets FDA Warning Over Contamination At RI Plant
• Husband Recounts Constant Pain At DePuy Hip Implant Trial
• Covidien Nets $177M From J&J Unit In Scalpel Patent Suit
• Fed. Circ. Rejects Bid To Add Inventors To MGH Gene Patents
• Medifast Freed From Investors' Securities Fraud Suit
• Quest Can't Duck Claims That It Pushed Out Older Sales Reps
• New MS Drug Approved By FDA Despite Teva's Opposition
• Pharmacies Lose Suit Calling CMS Rule Anti-Competitive
• Medicare Asleep On $70M Equipment Overpayments, OIG Says
• Wilson Sonsini Adds 5 Sidley Austin IP Litigation Attys
• W.Va. AG's Pill Mill Suit Kicked Back to State Court
• Gilead Poached Worker To Launch Rival Drug, Vertex Says
• Whisteblower Says Biotech Co. Used Family For US Contracts
• Deals Rumor Mill: Bain Capital, Dell, BayernLB
• 5 Things To Know About Oral Argument In FTC V. Actavis
• Litigation Support At A Crossroads
• BioMed Realty Strikes $640M Merger Deal With Wexford
• Fla. Judge Nixes Punitive Damages In Novartis Zometa Row
• Illumina Can't Revive DNA-Sequencing Patent Claims
• The Business End Of Supreme Court's Current Term
• Insurers Object To $4.8M Ferring, Aventis Antitrust Deal
• Pfizer Sues To Block Lupin's Generic Bladder-Control Drug
• Pfizer Settles Suit Over Rimadyl Dog Death
• Merck Atty's Letter Ruled Harmless In Whistleblower's Suit
• Walgreen, Insurer End Avastin Eye Injury Coverage Suit
• Fired Exec Slaps NY Hospital With $30M Defamation Suit
• Doc Gets 6 Years, To Pay $4.5M For Fen-Phen Settlement Fraud
• Doc-Owned Device Cos. Carry Fraud Risk, Inspector Warns
• Human Genome, GSK Dodge Lupus-Drug Suicide Suit
• Device Tax Repeal Faces Tough Slog Despite Senate Vote
• The 5 Litigators Sure To Drive Judges Mad
• Grand Jury Probe Sought In NECC Meningitis Outbreak
• Joining US, EU Probes Diabetes Drugs' Safety
• J&J Recalls 1.9M Blood Glucose Meters
• Life Sciences Rising Star: Gibson Dunn's Steven Tave
• DePuy Worker Warned Of Hip Design Problems, Jury Hears
• Actos 'Most Substantial' Factor In Man's Cancer, Doc Testifies
• Headset Maker Files Appeal Over €1B Blocked Sonova Sale
• Pfizer Wins Promotion Contract Row In Pa. Appeals Court
• What Food Cos. Can Learn From Horses And Peanuts
• 5 Tips For Making It Rain
• Chinese Vitamin Cos. To Pay $23M To Settle Price-Fixing Plot
• WR Grace Sues Teledyne Over Chemical-Process Patent
• Valeant's $344M Obagi Buy Rips Off Investors, Suit Says
• Okla. Device Ruling Puts Other Products In Crosshairs
• Latest FDA User Fee Bill Unlikely To Include Major Reforms
• Cooley Moves To Bigger Offices In Seattle
• Plaintiffs Attys Say Sky's Not Falling After CAFA Ruling
• Argon Pays $363M For Angiotech's Device Business
• NJ Panel Refuses To Revive Fosamax 'Jaw Death' Suit
• Lasik For Farsightedness Not Illegal Experiment: 9th Circ.
• Judge Stands By Decision Preempting DC Defamation Law
• High Court Split On Antitrust Test For Pay-For-Delay Deals
• Rising Star: Kirkland's Mike Shumsky
• FDA Challenges Execution Drug Ban In DC Circ.
• DePuy Hip Implants Appeared To Be Safe, Surgeon Testifies
• Watson Can't Skirt Shire's Colitis Drug Patent Suit
• Actavis, AstraZeneca Settle Crestor Generic Suit
• Sanofi Urges DC Circ. To Force Subpoena In Antitrust Suit
• FDA's New Device Review Policy Hits Some Speed Bumps
• Senate Signals Wide Support For $29B Device Tax Repeal
• Doc Testifies DePuy Hip Implant Debris Caused Bone Damage
• House Bill Aims To Limit Oxycodone Prescriptions
• Pfizer Settles With EPA On $205M NJ Superfund Cleanup
• Supreme Court Tames Class Action Frankenstein's Monster
• Mako Sues Rival Device Co. Over Robotic Surgery Patents
• Doc Testimony Over Discontinuing NuvaRing Axed From MDL
• MLB Says Clinic Hurt League By Hawking Drugs To Players
• Rising Star: Axinn Veltrop & Harkrider's Chad Landmon
• DC Circ. Defers To FDA In Stem Cell Device Marketing Row
• FDA Wants Tougher Scrutiny Of Emergency Defibrillators
• Nordion Settles Dr. Reddy's $80M Negligent Testing Suit
• Deals Rumor Mill: Life Technologies, PepsiCo, CVC Capital
• Life Sciences Cos. Faced 65% More Securities Suits In 2012
• Ky. Disbars Stanley Chesley Over $200M Fen-Phen Settlement
• Bayer Contests Consolidation Of Mirena IUD Defect Cases
• J&J Misled On Viactiv's Vitamin D Content, Suit Says
• 11th Circ. AndroGel Decision Bolsters FTC Pay-For-Delay Case
• AstraZeneca Pushes DC Circ. To Stretch Seroquel Exclusivity
• Va. Gov. Signs Nation's 1st Biosimilar Substitution Law
• Illumina Beats Life Tech DNA Patent Infringement Claims
• DC Circ. Blasts DEA Shipping Ban On Walgreen Facility
• AstraZeneca Places $420M Bet On Mass. Biotech Startup
• Delaware Rethinks Reverse Triangular Mergers
• In Re Hubbell Puts Inventors At A Disadvantage
• GOP Wins Promise Of Light Medical App Regulation From FDA
• 7 Reasons To Do Pro Bono Work
• Sanofi Investors Win Class Cert. In Obesity Drug Suit
• Stryker Can't Shake Hip Device Class Action
• Discovery Barred In Patent Re-Exams, Fed. Circ. Rules
• IP Atty Takes On Wall Street Over Herbalife 'Pyramid Scheme'
• Pay-For-Delay To Test High Court's Pro-Settlement Stance
• Pricey Pfizer Drug Spurs Call For NIH Collaboration Probe
• Bills Would Tighten Hydrocodone Dispensing Restrictions
• FDA Warnings Over Eye Infections Spark Partial Avastin Recall
• Ferring's Trade Secrets Claims Cut In $165M Patent Deal Row
• Valeant Inks $344M Deal For Skin Care Co. Obagi
• AstraZeneca Targets Actavis In Latest Nexium IP Suit
• Keep Watch Of French Authority's Pharma Sector Inquiry
• Avoid The Top 10 Pitfalls In A Jury Charge Conference
• Bayer Pays $24M To Settle Yaz, Yasmin Gallbladder Cases
• High Court's CAFA Ruling Carries Dangers For Defendants
• Class Action Lawyers React To Supreme Court's CAFA Ruling
• High Court Urged To Bar Fees For Untimely Vaccine Claims
• Jones Day Lures Atlanta FCA Experts From Nelson Mullins
• Bayer, Merial Fetch Win In Flea Medication MDL
• FDA Selects Interim Director For Office Of Generic Drugs
• McKesson Wages Suit Settlement May Harm Class, Judge Says
• Stryker Exec Who Jumped Ship Must Hand Over Trade Secrets
• Supreme Court Weighs Future Of Generic-Drug Defect Suits
• Walgreen Inks 10-Year Partnership Deal With Amerisource
• Lawmakers Push FDA To Finalize Mobile Health App Rules
• Affymax Mulls Bankruptcy After Anemia Drug Recall
• Deals Rumor Mill: Dell, Gazprom, Deutsche Telekom
• What You Should Know About PPACA Reporting Rules
• Justices Restore Class Action Fairness Act's Removal Power
• And Now A Word From The Panel ...
• FDA Approval Preempts DePuy Knee Device Suit, Judge Says
• Bingham Snags Transaction Experts From Foley, Dinsmore
• Cephalon Hit With FCA Suit Over Off-Label Marketing
• House Panel Readies Attack On FDA App Oversight
• Compounder Recalls All Products After Mold Found
• FDA Recommends Postponing Abbott MitraClip Approval
• WilmerHale Lands Ex-Ropes & Gray FDA Expert
• Justices Asked To Nix Fed. Circ. Claims Construction Rule
• FDA Told To Improve Complaints Tracking For Supplements
• Mistrial Declared In Merck's 1st Fosamax Femur Trial
• GSK, L'Oreal, Others Fined €39M Over Pricing Scheme
• Dendreon Pays $40M Over Claims It Inflated Provenge Demand
• Current Trends In FDA's Good Manufacturing Enforcement
• What Litigators Must Know About Va.'s 'Rocket Docket'
• UK Court Revokes 2 Novartis Patents In Bone Drug Row
• Historic Insider Trading Deal A Warning To Hedge Funds
• MDL Judge Limits Medical Fee Claims In 46 Novartis Suits
• For Biosimilar Developers, Honeymoon May Be Over
• Plaintiff Wants J&J Unit TCPA Junk Fax Suit Reopened
• HHS Updates State Medicaid FCA Compliance Rules
• West-Ward Lobs $175M False Ad Suit At Generic-Drug Rivals
• Ropes & Gray Skirts IP Malpractice Suit After Gunn Ruling
• Abbott Escapes Ensure Drinker's False Ads Suit
• Spectrum Pharmaceuticals Hit With Shareholder Class Action
• SAC Unit Will Pay $600M To Settle Insider Trading Claims
• Reading Tea Leaves After Amgen
• Syntrix Wins $96M Verdict Against Illumina In DNA Patent Suit
• FDA Says It Caved To Politics In Clearing ReGen Implant
• C.R. Bard Ducks FCA Suit Over Catheter Kickbacks
• Expert Networker Gets 1 Year For Passing Abaxis Tips
• FDA Warns Fresenius Medical Over Dialysis Device
• Teva To Pay $2M To Resolve Toxic Discharge Suit
• FDA Generic-Drug Leader Steps Down Amid Agency Changes
• Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal
• Jury Finds Chinese Vitamin C Makers Fixed Prices
• FDA Will Probe Diabetes Drug Safety Risk Report
• High Court Urged By Doctors To Uphold Myriad Gene Patents
• Abbott Accuses Ex-VP, Boston Scientific Of Raiding Sales Staff
• How FDA Differs From CMS In Clinical Lab Test Oversight
• FDA's Risk-Benefit Plan May Drive More Drug Approvals
• Dr. Reddy's Still Can't Duck Suit Over Generic Angiomax
• Forest Labs Can't Escape Class Action Over Junk Faxes
• DLA Piper Snags Global IP Pro From Squire Sanders
• Icahn, Banks Propping Up Herbalife Scheme, Short-Seller Says
• Endo Medical Mesh Suit Booted Back To Calif. Court
• Insurer Disputes Duty To Defend In Drug Co.'s Pill Mill Suit
• Fla. House Panel Approves Bill To Beef Up State FCA
• Mylan Settles Fortamet Patent Suit With Shionogi, Andrx
• FDA Can Regulate Stem Cell Treatment As Drug, DC Circ. Hears
• 6th Circ. Says Pliva Failure-To-Warn Claims Not Preempted
• IMS Health Inks $100M Deal For Marketing Software Firm
• Foley & Lardner Accused Of Botching Medical Patent Suits
• The Outer Limits Of Expert Testimony Gatekeeping
• Class Cert. Bid Flawed In Transitions Antitrust Row: Judge
• FTC's Take On Drug Sales To Rivals May Cost Pharma
• Stryker Warned By FDA For Marketing Of Recalled Device
• Medtronic Fights $10M Catheter IP Verdict In Fed. Circ.
• Merck's Fosamax Caused Femur Fractures, Jury Hears
• Carolina Casualty Can't Dodge FCA Coverage
• FDA Promoted Illegal Compounding, KV Tells DC Circ.
• Waiora Pays $12M To Settle Suit Over Anti-Aging Supplement
• Polsinelli Nabs Health Pro With FCPA Chops From Mintz Levin
• Remember To Pay Attention To Antitrust Standing Issues
• Kline & Specter Sues 2 Firms Over GSK Dental Cream Deals
• Pfizer Antibiotic Linked To Deadly Heart Disorder, FDA Warns
• House Bill Would Authorize Medicare Drug Price Negotiations
• DC Circ. Rules FDA Properly Approved Skin Oil Generics
• A Bitter Loss For POM Signals More FTC Scrutiny
• Deals Rumor Mill: KKR, Carlyle, Lenovo
• Hedge Fund Creator Decries SEC's Attempt At D&O Ban
• Pfizer Deal Marks A Missed Chance For Branded-Drug Cos.
• 'Knockoff' Blood Clot Product Still On Market: Supplement Co.
• CORRECTED: Insurer Says Cracked Security System Led To $80M Lilly Theft
• Blaming Vitamin C Price Hike On SARS Absurd, Jury Hears
• State AGs Push For Abuse-Resistant Generic Painkillers
• 6th Circ. Says $3B Dow Deal Requires Authorization Of Credits
• Myriad Defends Cancer Gene Patents To Supreme Court
• High Court Asked To Hear Generic Reglan Design Defect Suit
• Expert Networker's Insider Trading Warrants Prison, US Says
• J&J's Win Upheld In Antibody Patent Fight Against Abbott
• Mylan Says Teva's MS Drug IP Suit Doomed By Safe Harbor
• Merck, BMS Target Hetero Over Generic HIV Drug Sustiva
• Getting The Wrinkles Out Of Anti-Aging Products
• Corning To Pay $6M To Settle GSA False Claims Suit
• Glenmark Asks Fed. Circ. To Nix Patent In $16M Abbott Win
• Warner 'Confused' About Doryx Contracts, Retailers Say
• FDA's New Safety Reports Raise Tort Risks For Device Cos.
• Sanofi Facing DOJ Investigation Over Plavix Disclosures
• Law360 Names Top Attorneys Under 40
• Lupin Can't Escape Gilead's Ranexa Patent Suit
• Judge Sides With Allergan On Eyelash-Growth Patent Claim
• AstraZeneca Affiliate Wants Ch. 11 Nixed Due To Cost
• Fujifilm, GE Near Escape From Tumor Monitoring Patent Suit
• DePuy Hit With $8.3M Verdict Over Metal Hip Implant
• FDA Urges More Accuracy On 'Latex Free' Med Supply Labels
• Wash. High Court Won't Let Insurers Recoup Defense Costs
• Warner Chilcott Misbranded Drugs, FCA Kickback Suit Says
• Icahn Raises Herbalife Stake To 15.5% Amid Ackman Fight
• Takeaways From FDA's 1st Waiver Decision
• FDA Unveils Draft Plan For New Benefit-Risk Framework
• Amazon Accused Of 'Bait-And-Switch' In Supplement Ads
• Insurers Sue To Shirk Defense Of J&J Counterfeiting Suit
• Pa. Appeals Court Tosses Paxil Birth Defect Suit
• Whistleblower Can Pursue FCA Suit Over Vascular Treatments
• Off-Label Drug Coverage Bill Clears NJ Assembly Panel
• EU Food Business Operators Still Have A Lot To Chew Over
• Immucor Puts Up $4M To Settle Price-Fixing Coverup Claims
• Affymax Sued Over $500M Stock Drop Linked To Recall
• Teva's Defective IUD Caused Injuries, $15M Suit Says
• Ranbaxy Ducks Wider Recall In Glass Particles Class Action
• Shire Wins Dismissal Of Adderall Antitrust Suit
• $85M Default Risk Keeps K-V Pharma Ch. 11 Plan On Schedule
• 5th Circ. Upholds Block On Blood Clot Supplement 'Knockoff'
• Ferring, Aventis To Pay $4.8M To End Drug Antitrust Suit
• Royalty Keeps Pushing $6.6B Buyout Despite Elan's Refusal
• More FDA Detention Slips For Food Cos.
• A Look At The Health Care M&A Horizon
• AstraZeneca Escapes $100M AWP Suit Over Nexium
• FDA Issues Guidelines For Back-And-Forth In Device Reviews
• FDA Says Hospira Plant Continues To Have Quality Issues
• FDA Again Delays Expanded Use Of Blood Thinner Xarelto
• Pfizer Beats Medicare Fraud Suit Over Pain Patch Marketing
• Budget Bill Includes Fix For FDA's Medical Device User Fees
• GSK, Thalidomide Plaintiffs Spar Over Pa., Federal Jurisdiction
• 9th Circ. Upholds Ex-InterMune CEO's Fraud Conviction
• Express Scripts Says Class Action's Recall Bid Hits FDA Turf
• Impax Still Needs To Fix Production Plant Issues, FDA Says
• Pfizer Targets Generic Celebrex After Extending Patent
• Par To Pay $45M For Off-Label Marketing Of AIDS Drug
• Fen-Phen Claimant Wrongly Denied Benefits, 3rd Circ. Told
• A New Trend In Health Care Fraud Settlements
• MIT Loses Ownership Bid In IP Row Over Anti-Cancer Device
• Pfizer Ducks Class Cert. In ERISA Suit Over Wyeth Merger
• House GOP Fears ACA's Device Tax Could Hit Smartphones
• Novartis Hit With $250K Verdict In Zometa Jaw Injury Suit
• Baxter Urges Fed. Circ. Not To Reopen Fresenius Battle
• Drug Biz Wants Strong IP Measures In Pacific Trade Pact
• Healthpoint, DFB Settle With Pa. In Skin Ointment FCA Row
• Chinese Vitamin C Makers Fabricated Export Docs, Jury Told
• XL, Ace Off The Hook For $850M Seroquel Defense Costs
• Novartis Gets NJ Damages Applied To Fla. Bone Drug Suit
• Novo Nordisk Asks Fed. Circ. To Save Prandin Patent
• Zimmer, Marketing Co. Win New Trial In Knee Injury Case
• Roche Appeals Recusal Ruling In NJ Accutane Suits
• Elan Sweetens Deal To Counter $6.6B Takeover Bid
• Promega Seeks New Trial In Gene-Testing Patent Row
• 1st-To-File System Isn't New To Drug Companies
• The Pressure Is On For 340B Entities
• Sun Pharma Demands Generic Cancer Drug Market Exclusivity
• Depomed Targets Generics Maker Over Diabetes Drug IP
• Chancellor Strine's View On Disclosures Evolving, Attys Say
• Pill Maker Settles $100M Insurance Row Over Thailand Flood
• Angina Drug's Minty Taste, Smell Can't Be Trademarked: TTAB
• Merck To Kick Off 2nd Round Of Fosamax Suits In NJ
• K-V Creditors Ask Judge To Delay Ch. 11 Plan Hearing
• Momenta, Sandoz Ask Justices To Clarify Safe Harbor Rule
• Lance Armstrong Endorsements Founded On Lies, Class Says
• FDA's Facebook Slap Gives Drug Industry Little To Like
• Roche Inches Closer To Escaping Accutane MDL
• Supreme Court Warned Of Risks Of Banning Pay-For-Delay